尼达尼布治疗系统性硬化症相关间质性肺病的真实世界疗效与安全性:一项意大利多中心研究数据
该意大利多中心研究回顾性评估了90例系统性硬化症相关间质性肺病(SSc-ILD)患者使用尼达尼布(NTD)的疗效与安全性。NTD引入后12个月,%pFVC保持稳定(64±14降至62±19,p=0.416),显著肺进展患者比例较前12个月降低(60% vs 17.5%,p=0.007);胃肠道不良反应见于35例(39%)。作者认为NTD联合免疫抑制剂可能稳定肺功能。
要点
- NTD引入后12个月%pFVC保持稳定(64±14降至62±19,p=0.416)。
- 12个月时显著肺进展比例低于前12个月(60% vs 17.5%,p=0.007)。
- 胃肠道不良反应见于35例(39%),部分患者经剂量调整后维持NTD。
核心结论
- 在真实临床场景中,NTD联合免疫抑制剂可能稳定SSc-ILD患者的肺功能。
- 胃肠道不良反应常见,可能需要调整NTD剂量以维持用药。
研究设计与样本
- 意大利多中心研究,回顾性评估接受NTD治疗的SSc-ILD患者,分别在NTD引入前12个月、基线及NTD引入后12个月进行评价。
- 共纳入90例SSc-ILD患者(65%女性,平均年龄57.6±13.4岁,平均病程8.8±7.6年)。
- 75%患者抗拓扑异构酶I抗体阳性,77例(85%)患者使用免疫抑制剂。
主要发现
- NTD引入前12个月,60%患者出现%pFVC显著下降。
- NTD引入后12个月,40例(44%)患者有随访数据,%pFVC保持稳定(64±14降至62±19,p=0.416)。
- 12个月时显著肺进展患者比例显著低于前12个月(60% vs 17.5%,p=0.007)。
- mRSS未见显著变化;胃肠道不良反应见于35例(39%)患者。
- 23例(25%)患者在平均3.6±3.1个月后经剂量调整维持NTD;9例(10%)患者在中位4.5(1-6)个月后停用NTD;随访期间4例患者死亡。
临床怎么用
- 作者认为,在真实临床场景中NTD联合免疫抑制剂可能稳定SSc-ILD患者的肺功能。
- 作者指出胃肠道不良反应常见,可能需要调整NTD剂量以维持用药。
局限性
- 原文为回顾性评估。
- NTD引入后12个月随访数据仅40例(44%)患者可用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Nintedanib (NTD) has been shown to be effective in systemic sclerosis (SSc)-interstitial lung disease (ILD). Here we describe the efficacy and safety of NTD in a real-life setting. METHODS: Patients with SSc-ILD treated with NTD were retrospectively evaluated at 12 months prior to NTD introduction; at baseline and at 12 months after NTD introduction. The following parameters were recorded: SSc clinical features, NTD tolerability, pulmonary function tests and modified Rodnan skin score (mRSS). RESULTS: 90 patients with SSc-ILD (65% female, mean age 57.6±13.4 years, mean disease duration 8.8±7.6 years) were identified. The majority were positive for anti-topoisomerase I (75%) and 77 (85%) patients were on immunosuppressants. A significant decline in %predicted forced vital capacity (%pFVC) in the 12 months prior to NTD introduction was observed in 60%. At 12 months after NTD introduction, follow-up data were available for 40 (44%) patients and they showed a stabilisation in %pFVC (64±14 to 62±19, p=0.416). The percentage of patients with significant lung progression at 12 months was significantly lower compared with the previous 12 months (60% vs 17.5%, p=0.007). No significant mRSS change was observed. Gastrointestinal (GI) side effects were recorded in 35 (39%) patients. After a mean time of 3.6±3.1 months, NTD was maintained after dose adjustment in 23 (25%) patients. In nine (10%) patients, NTD was stopped after a median time of 4.5 (1-6) months. During the follow-up, four patients died. CONCLUSIONS: In a real-life clinical scenario, NTD, in combination with immunosuppressants, may stabilise lung function. GI side effects are frequent and NTD dose adjustment may be necessary to retain the drug in patients with SSc-ILD.
引用
- Campochiaro C, De Luca G, Lazzaroni MG, et al. Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study. RMD Open. 2023. PMID: 36813476. doi:10.1136/rmdopen-2022-002850
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。